The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma DOI Creative Commons
Léon Raymakers, Elsemieke M. Passchier, Meggy E.L. Verdonschot

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(9), P. 632 - 632

Published: April 24, 2025

The efficacy of immunotherapy in pancreatic ductal adenocarcinoma (PDAC) remains limited. tumor microenvironment (TME), characterized by the accumulation suppressive myeloid cells including neutrophils, attributes to resistance PDAC. IgA monoclonal antibodies (mAbs) can activate neutrophils kill cells; this be further enhanced blocking immune checkpoint CD47. In study, we investigated potential therapeutic strategy for We determined expression tumor-associated antigens (TAAs) on PDAC cell lines and fresh patient samples, results showed that TAAs epithelial adhesion molecule (EpCAM), trophoblast surface antigen 2 (TROP2) mucin-1 (MUC1), as well CD47 were consistently expressed line with this, mAbs against EpCAM lyse various cells, which augmented addition blockade. addition, observed present tumors receptor IgA. conclusion, our indicate a combination mAb blockade is promising preclinical treatment PDAC, merits investigation.

Language: Английский

From surfing to diving into the tumor microenvironment through multiparametric imaging mass cytometry DOI Creative Commons
Marco Erreni, Maria Rita Fumagalli,

M Marozzi

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 11, 2025

The tumor microenvironment (TME) is a complex ecosystem where malignant and non-malignant cells cooperate interact determining cancer progression. Cell abundance, phenotype localization within the TME vary over development in response to therapeutic interventions. Therefore, increasing our knowledge of spatiotemporal changes architecture importance better understand etiologic neoplastic diseases. Imaging Mass Cytometry (IMC) represents elective multiplexed imaging technology enabling in-situ analysis up 43 different protein markers for in-depth phenotypic spatial investigation their preserved microenvironment. IMC currently applied research define composition cellular landscape identify biomarkers predictive prognostic significance with relevance mechanisms drug resistance. Herein, we describe general principles experimental workflow raising informative potential preclinical clinical research.

Language: Английский

Citations

0
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma DOI Creative Commons
Léon Raymakers, Elsemieke M. Passchier, Meggy E.L. Verdonschot

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(9), P. 632 - 632

Published: April 24, 2025

The efficacy of immunotherapy in pancreatic ductal adenocarcinoma (PDAC) remains limited. tumor microenvironment (TME), characterized by the accumulation suppressive myeloid cells including neutrophils, attributes to resistance PDAC. IgA monoclonal antibodies (mAbs) can activate neutrophils kill cells; this be further enhanced blocking immune checkpoint CD47. In study, we investigated potential therapeutic strategy for We determined expression tumor-associated antigens (TAAs) on PDAC cell lines and fresh patient samples, results showed that TAAs epithelial adhesion molecule (EpCAM), trophoblast surface antigen 2 (TROP2) mucin-1 (MUC1), as well CD47 were consistently expressed line with this, mAbs against EpCAM lyse various cells, which augmented addition blockade. addition, observed present tumors receptor IgA. conclusion, our indicate a combination mAb blockade is promising preclinical treatment PDAC, merits investigation.

Language: Английский

Citations

0